Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Novel in vivo models of optic atrophy show pathological changes in mitochondrial structure and function
Author Affiliations & Notes
  • Elin Strachan
    SBBS, University College Dublin, Dublin, Ireland
    Conway Institute, University College Dublin, Dublin, Ireland
  • Eugene Dillon
    SBBS, University College Dublin, Dublin, Ireland
    Conway Institute, University College Dublin, Dublin, Ireland
  • Benjamin Delprat
    MMDN, Montpellier Universite d'Excellence, Montpellier, Occitanie, France
    INM, Montpellier Universite d'Excellence, Montpellier, Occitanie, France
  • Breandan N Kennedy
    SBBS, University College Dublin, Dublin, Ireland
    Conway Institute, University College Dublin, Dublin, Ireland
  • Niamh C O'Sullivan
    SBBS, University College Dublin, Dublin, Ireland
    Conway Institute, University College Dublin, Dublin, Ireland
  • Footnotes
    Commercial Relationships   Elin Strachan None; Eugene Dillon None; Benjamin Delprat None; Breandan Kennedy None; Niamh O'Sullivan None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2553. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elin Strachan, Eugene Dillon, Benjamin Delprat, Breandan N Kennedy, Niamh C O'Sullivan; Novel in vivo models of optic atrophy show pathological changes in mitochondrial structure and function. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2553.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Optic atrophy (OA) is a form of inherited optic neuropathy, characterised by progressive and irreversible degeneration of retinal ganglion cells (RGCs). This degeneration subsequently leads to sight loss, for which there is presently no treatment. Most OA patients have mutations in the mitochondrial fusion protein OPA1. It is unclear why OPA1 mutations lead to RGC death and subsequent vision loss.

Methods : CRISPR/Cas9 gene editing was used to disrupt the endogenous Opa1 gene of Fruit flies (Drosophila melanogaster) and zebrafish (Danio rerio). The fly knockout (KO) model was generated using the UAS-GAL4 system to create neuron-specific expression of CRISPR guides. In zebrafish, CRISPR guides injected into embryos created an 800 bp deletion in the Opa1 GTPase domain. PCR and qPCR validated editing events in both models. In flies, fluorescence microscopy was used to assess mitochondrial morphology. Optokinetic response assays were used to assess vision in zebrafish. Transmission electron microscopy and Seahorse extracellular flux assays were used to examine mitochondrial morphology and function in zebrafish larvae. Fluorescence microscopy was used in conjunction with the Tg(isl2b:mitoeGFP-2ATagRFPCAAX) line to look at RGC morphology in KO zebrafish larvae. Mass spectrometry was used for proteomic analysis of both models.

Results : qPCR confirmed reductions in Opa1 expression in both the Crispant (~75%, p<0.01) and fruit fly (~35%, p<0.01) models. Neuron-specific KO flies have more rounded mitochondria (p<0.0001). Zebrafish opa1 crispants display a significant (p<0.01) loss of visual acuity compared to buffer-injected siblings. Crispant larvae have dysfunctional respiration according to several metrics, including a 15% reduction in maximal respiration (p<0.05). Provisional TEM results suggest accumulation of rounded mitochondria in the optic nerve of zebrafish larvae, which was corroborated by fluorescence imaging. Proteomic analysis indicated mitochondrial dysfunction in the crispants, which was confirmed through seahorse assays, that showed various respiratory defects including reduced basal respiration (p<0.01).

Conclusions : Opa1 loss of function models were created in both zebrafish and flies. These will be used to study the pathological mechanisms underlying Opa1-mediated vision loss. The phenotypic changes described can be used for screening potential therapies for Opa1-linked OA.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×